Skip to content
Bomb Report – Lifestyle
Author:
Trintech, Inc.
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 7, 2026
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
May 7, 2026
Trintech Named a 2026 Best and Brightest Company to Work For® in Dallas/Fort Worth and Nationwide
April 16, 2026
Trintech Advances Financial Close with Agentic AI Built for Finance
April 9, 2026
Trintech Named to the 2026 Inc. Regionals List of the Fastest-Growing Private Companies in the Southwest
April 1, 2026
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 30, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
6 of the Top 10 Global Banks Trust Trintech to Power Daily Reconciliation and Financial Close
March 12, 2026
Trintech Announces FY26 Partner Award Winners
March 5, 2026